Survival Benefit Persists at 3 Years With Durvalumab Plus Chemo in Advanced Biliary Tract Cancer
Superior 3-year survival outcomes were observed with durvalumab plus chemotherapy compared with chemotherapy alone in patients with advanced biliary tract cancer.